Skip to main content
Top
Published in: Updates in Surgery 6/2022

03-09-2022 | Pleural Mesothelioma | Original Article

Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR)

Authors: Dimitrios E. Magouliotis, Prokopis-Andreas Zotos, Arian Arjomandi Rad, Despoina Koukousaki, Vasiliki Vasilaki, Ioustini Portesi, Kyriakos Spiliopoulos, Thanos Athanasiou

Published in: Updates in Surgery | Issue 6/2022

Login to get access

Abstract

Objective

We reviewed the available literature on patients with MPM undergoing either extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D).

Methods

Original research studies that evaluated long-term outcomes of P/D versus EPP were identified, from January 1980 to February 2022. The 30-days and 90-day mortality, along with the 1-, 2-, 3-, 5-year survival, the median overall survival, the macroscopic complete resection (MCR) rate, and the complications were calculated according to both a fixed and a random effect model. The Q and I2 statistic were used to test for heterogeneity among the studies. Sensitivity analysis was performed including only studies that incorporated the MCR concept.

Results

Eighteen studies were included, incorporating a total of 4,852 patients treated with EPP and P/D. The 30-day mortality was significantly higher in the EPP group (OR: 2.79 [95% CI 1.30, 6.01]; p = 0.009). The median overall survival was higher in the P/D group (WMD:-4.55 [-6.05, -3.04]; p < 0.001). No differences were found regarding the 90-day mortality, MCR rate, and the 1-, 2-,3-, 5-year survival between the EPP and P/D groups. These findings were validated by the sensitivity analysis. The incidence of atrial fibrillation, hemorrhage, pulmonary embolism, air leak, and reoperation was significantly increased in the EPP group (p < 0.05).

Conclusions

The present meta-analysis indicates that P/D is associated with enhanced outcomes regarding 30-day mortality, median overall survival, and complications. The P/D approach should be preferred when technically feasible. However, the procedure of choice should be decided based on the goal of MCR in the safest approach for the patient.
Appendix
Available only for authorised users
Literature
1.
go back to reference TuralOnur S, Sokucu SN, Dalar L, Iliaz S, Kara K, Buyukkale S et al (2016) Are neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? Ther Clin Risk Manag 12:651–656CrossRef TuralOnur S, Sokucu SN, Dalar L, Iliaz S, Kara K, Buyukkale S et al (2016) Are neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? Ther Clin Risk Manag 12:651–656CrossRef
2.
go back to reference Sugarbaker DJ, Wolf AS, Chirieac LR, Godleski JJ, Tilleman TR, Jaklitsch MT et al (2011) Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg 40:298–303PubMed Sugarbaker DJ, Wolf AS, Chirieac LR, Godleski JJ, Tilleman TR, Jaklitsch MT et al (2011) Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg 40:298–303PubMed
3.
go back to reference Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J et al (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–772CrossRefPubMedPubMedCentral Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J et al (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–772CrossRefPubMedPubMedCentral
4.
go back to reference Rusch V, Baldini EH, Bueno R et al (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston. Mass J Thorac Cardiovasc Surg 145:909–910CrossRefPubMed Rusch V, Baldini EH, Bueno R et al (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston. Mass J Thorac Cardiovasc Surg 145:909–910CrossRefPubMed
5.
go back to reference Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6(8):1304–1312. https://doi.org/10.1097/JTO.0b013e3182208e3fCrossRefPubMed Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6(8):1304–1312. https://​doi.​org/​10.​1097/​JTO.​0b013e3182208e3f​CrossRefPubMed
6.
go back to reference Taioli E, Wolf AS, Flores RM (2015) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99:472–480CrossRefPubMed Taioli E, Wolf AS, Flores RM (2015) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99:472–480CrossRefPubMed
8.
go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009 Jul 21;6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100. Epub 2009 Jul 21. PMID: 19621070; PMCID: PMC2707010. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009 Jul 21;6(7):e1000100. https://​doi.​org/​10.​1371/​journal.​pmed.​1000100.​ Epub 2009 Jul 21. PMID: 19621070; PMCID: PMC2707010.
9.
go back to reference Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Accessed on 8 jan 2022. www.cochrane-handbook.org Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Accessed on 8 jan 2022. www.​cochrane-handbook.​org
10.
go back to reference Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed
11.
go back to reference Aziz T, Jilaihawi A, Prakash D (2002) The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 22(2):298–305CrossRefPubMed Aziz T, Jilaihawi A, Prakash D (2002) The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 22(2):298–305CrossRefPubMed
13.
go back to reference Branscheid D, Krysa S, Bauer E, Bülzebruck H, Schirren J (1991) Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 5(9):466–472 (discussion 473). Branscheid D, Krysa S, Bauer E, Bülzebruck H, Schirren J (1991) Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 5(9):466–472 (discussion 473).
14.
go back to reference de Vries WJ1, Long MA (2003) Treatment of mesothelioma in Bloemfontein, South Africa. Eur J Cardiothorac Surg 24(3):434–440 de Vries WJ1, Long MA (2003) Treatment of mesothelioma in Bloemfontein, South Africa. Eur J Cardiothorac Surg 24(3):434–440
15.
go back to reference Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620–626. https://doi.org/10.1016/j.jtcvs.2007.10.054(626.e1–3) Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620–626. https://​doi.​org/​10.​1016/​j.​jtcvs.​2007.​10.​054(626.e1–3)
22.
go back to reference Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N (2008) Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 7(1):102–106CrossRefPubMed Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N (2008) Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 7(1):102–106CrossRefPubMed
23.
go back to reference Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM (1997) Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4(3):215–222CrossRefPubMed Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM (1997) Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4(3):215–222CrossRefPubMed
25.
go back to reference Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS, et al (2008) Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 85(1):257–64 (discussion 264) Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS, et al (2008) Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 85(1):257–64 (discussion 264)
29.
go back to reference Rusch V, Baldini EH, Bueno R, De Perrot M, Flores R, Hasegawa SJ (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston. Mass Thorac Cardiovasc Surg 145(4):909–910. https://doi.org/10.1016/j.jtcvs.2013.01.039CrossRef Rusch V, Baldini EH, Bueno R, De Perrot M, Flores R, Hasegawa SJ (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston. Mass Thorac Cardiovasc Surg 145(4):909–910. https://​doi.​org/​10.​1016/​j.​jtcvs.​2013.​01.​039CrossRef
Metadata
Title
Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR)
Authors
Dimitrios E. Magouliotis
Prokopis-Andreas Zotos
Arian Arjomandi Rad
Despoina Koukousaki
Vasiliki Vasilaki
Ioustini Portesi
Kyriakos Spiliopoulos
Thanos Athanasiou
Publication date
03-09-2022
Publisher
Springer International Publishing
Published in
Updates in Surgery / Issue 6/2022
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI
https://doi.org/10.1007/s13304-022-01369-4

Other articles of this Issue 6/2022

Updates in Surgery 6/2022 Go to the issue